Diabetes May Short Circuit Pembrolizumab Benefits in NSCLC Diabetes May Short Circuit Pembrolizumab Benefits in NSCLC
The new study shows a correlation between diabetes and poor outcomes for patients with metastatic non –small cell lung cancer (NSCLC) who received pembrolizumab.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Diabetes | Endocrinology | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Study